What Is Retatrutide? Understanding the Triple Agonist Peptide
Retatrutide is an investigational Eli Lilly peptide, research code LY3437943, that switches on three hormone receptors together, namely GIP, GLP-1 and glucagon. Hitting all three is the reason it delivered bigger weight reductions in trials than single or dual agonists did. No regulator has approved it so far, and phase 3 results were still coming out during 2026.
Buy Retatrutide Australia Labs Order, and Learn What the Peptide Is Made Of
Is retatrutide a peptide? It is. The molecule is a 39 amino acid chain whose backbone comes from GIP (glucose-dependent insulinotropic polypeptide), engineered so that the very same chain also activates the GLP-1 and glucagon receptors. It is not a steroid, and neither its chemistry nor its pharmacology has anything in common with anabolic steroids.
Most of the heavy lifting is done by three features of the sequence.
- Non-coded amino acids. Positions 2 and 20 carry aminoisobutyric acid (Aib), and position 13 carries alpha-methyl-L-leucine. The Aib at position 2 shields the peptide from DPP-4, the enzyme that chops native GLP-1 and GIP apart within minutes.
- A fatty acid side chain. A linker connects a C20 fatty diacid to the lysine at position 17. This chain attaches to albumin in the blood and so slows clearance.
- A C-terminal tail borrowed from the exendin family, which helps keep the molecule stable.
Its molecular weight comes to about 4.73 kDa. In the lab that number is important, since it is precisely what a mass spectrometry identity test compares against. When you buy retatrutide online in Australia from NovaPep, that mass is confirmed for every 10, 20 or 30 mg lot.
Order Retatrutide Online and See How It Works on Three Receptors
Retatrutide acts on three receptors, and each one governs a different side of energy balance.
- GLP-1 receptor. It drives glucose-dependent insulin release, slows stomach emptying and sends satiety signals in the brain. Semaglutide works through this receptor.
- GIP receptor. This is the second incretin pathway, playing a part in insulin release and in how fat tissue handles lipids. Tirzepatide combines it with GLP-1. Order tirzepatide online as a 2 mg research vial for GIP and GLP-1 comparisons.
- Glucagon receptor. Working mostly in the liver, it raises energy expenditure and fat breakdown. This is the novel component.
The three are intentionally out of balance. A 2024 structural paper in Cell Discovery summarised retatrutide as roughly 8.9 times more potent than native GIP at the GIP receptor. At their own receptors, however, it was only around 0.4 times as potent as native GLP-1 and 0.3 times as potent as native glucagon. In practice, then, what does retatrutide do? It relies most heavily on GIP, retains enough GLP-1 activity for its appetite effects, and adds partial glucagon activity to drive energy expenditure and liver fat loss without the rise in blood sugar that full glucagon agonism would bring.
Shop Retatrutide for Sale With Its Half-Life Explained
In humans retatrutide has a half-life of around six days, a figure taken from the phase 1b multiple-ascending-dose study in people with type 2 diabetes (Urva et al., The Lancet, 2022). This explains why all of the clinical trials have dosed once a week. By contrast, native GLP-1 survives about two minutes in circulation and native GIP just a few minutes, so it is the albumin-binding fatty acid that makes retatrutide workable in the first place.
For a laboratory, the relevant half-life is really shelf stability, not plasma clearance. Keep the freeze-dried powder frozen at minus 20 °C, and once it has been reconstituted, store the vial in the fridge at 2 to 8 °C and use it within four weeks. The reasons are set out in our peptide storage guide, and reconstitution volumes for every vial size are worked out by the retatrutide calculator.
Buy Retatrutide Knowing the Benefits Reported in Clinical Trials
Every retatrutide benefit described to date is a trial outcome rather than a proven clinical benefit, because regulators have not yet reviewed the data. These are the headline results.
- Weight. The phase 2 obesity trial (New England Journal of Medicine, 2023) found the 12 mg group lost 24.2% of body weight on average after 48 weeks, compared with 2.1% on placebo. In the phase 3 TRIUMPH-1 trial, Lilly reported a 28.3% loss after 80 weeks on 12 mg.
- Blood glucose. For type 2 diabetes, the phase 2 trial (The Lancet, 2023) recorded HbA1c falls of up to 2.02 percentage points after 24 weeks, and the phase 3 TRANSCEND-T2D-1 trial recorded falls of up to about 2.0 points after 40 weeks.
- Liver fat. The phase 2a substudy (Nature Medicine, 2024) found an 86.0% reduction in liver fat after 48 weeks on 12 mg.
- Joint pain. In people with knee osteoarthritis, TRIUMPH-4 reported major gains in pain scores together with 28.7% weight loss after 68 weeks on 12 mg.
For a week-by-week and dose-by-dose breakdown, see our retatrutide results guide.
Order Retatrutide and Understand What It Is Used For Today
At present retatrutide has only two uses, registered clinical trials and laboratory research. Lilly is testing it in obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis pain, chronic low back pain, kidney disease and cardiovascular outcomes. In July 2026 Lilly announced that its FDA submission would now arrive in early 2027, citing the need to gather more manufacturing and quality data.
For research labs, retatrutide serves as a tool compound for exploring how the three receptors interact. Since a single molecule covers all three, a study can set it against a dual agonist like tirzepatide, a GLP-1-only compound, or an amylin analogue like cagrilintide to tease apart each pathway's contribution. Our retatrutide vs tirzepatide guide gives the side-by-side detail.
Shop Retatrutide With the Side Effects Summarised
Side effects in the trials match the usual incretin profile. Nausea, diarrhoea, vomiting and constipation dominate, rising with dose and clustering during escalation, along with an increase in resting heart rate. Phase 3 also turned up a skin-sensation effect called dysesthesia at the higher doses. All the figures are in our guide to retatrutide side effects.
Retatrutide does not appear on the ARTG in Australia, and the TGA has cautioned against using it outside clinical trials after testing found products sold as retatrutide that were contaminated or contained a different drug altogether.
Buy the Best Peptide to Pair With Retatrutide in Research
So what is the best peptide to take with retatrutide? Looking at the published research, the answer is really a comparison compound rather than a companion. Tirzepatide shares two of the three receptors, so running it alongside retatrutide isolates the glucagon effect, while cagrilintide brings in the amylin pathway. Cagrilintide is for sale in Australia in 5 and 10 mg vials for labs adding the amylin pathway. We do not give advice on combinations outside a laboratory.
Buy Retatrutide Online in Australia as Vials, a Pen or a Starter Kit
We stock retatrutide as lyophilised powder in three vial fills (10, 20 and 30 mg), and also as the Retatrutide Pen, which carries 10 mg in solution inside a 3 mL multi-dose cartridge for labs that prefer to avoid reconstitution. An outside laboratory tests every lot, using mass spectrometry for identity and HPLC for purity, and the lot number on your vial can be looked up on the COA lookup page. The other incretin and amylin compounds are grouped in our metabolic research peptides range.
Choosing is straightforward. Order the retatrutide vial if your lab reconstitutes peptides as a matter of routine, since dry powder lasts longest and the 30 mg fill offers the lowest cost per milligram. Pick the pen when a short study would prefer no reconstitution at all. First-time buyers tend to get the most from the retatrutide starter kit, which puts the peptide, 3 mL of diluent and one insulin syringe in one box. Order online, compare lot certificates, and buy the size your protocol calls for.
For laboratory research only. NovaPep sells to adults 18+, and none of our products are intended for people or animals.
What Is Retatrutide? Understanding the Triple Agonist Peptide FAQ
What does retatrutide do in research models?
Retatrutide switches on three receptors. GLP-1 and GIP drive insulin release and appetite signalling, and glucagon lifts energy expenditure and lowers liver fat. In trials the result was mean weight reductions of up to 24.2% after 48 weeks in phase 2 and 28.3% after 80 weeks in phase 3, along with better blood glucose in type 2 diabetes.
Is retatrutide actually a peptide?
It is. Retatrutide is a peptide of 39 amino acids on a backbone derived from GIP, with unnatural amino acids that hold off enzymes and an albumin-binding C20 fatty acid chain. Steroids are a different class altogether. A molecular weight of about 4.73 kDa is what mass spectrometry checks when identity is tested.
How long is the half-life of retatrutide?
In humans retatrutide has a half-life of roughly six days, according to the phase 1b trial published in The Lancet in 2022. That long half-life results from the fatty acid side chain attaching to albumin in the blood, and it explains why every clinical trial has given it once a week.
Which company makes retatrutide?
Eli Lilly discovered retatrutide and is developing it, the same company that makes tirzepatide (Mounjaro). The research code is LY3437943. Lilly runs the TRIUMPH phase 3 programme in obesity and related conditions as well as the TRANSCEND programme in type 2 diabetes, and plans to seek FDA approval in early 2027.
Has retatrutide been approved?
No. At the time of writing no regulator, the FDA and the TGA included, had approved retatrutide, and the Australian Register of Therapeutic Goods has no entry for it. Lilly expects to file in the US early in 2027, with other countries following on their own timelines.
Where do I buy retatrutide in Australia?
NovaPep sells retatrutide online strictly for laboratory research. From Australian stock you can order three vial sizes, the pen or the starter kit, with a certificate from an independent testing laboratory supplied for each lot. Because retatrutide is not on the ARTG, it cannot be purchased as an approved medicine, and research vials are not for human use.